Contrast Enhanced Ultrasound

Global Contrast Enhanced Ultrasound Market to Reach US$2.7 Billion by 2030

The global market for Contrast Enhanced Ultrasound estimated at US$2.1 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Ultrasound Equipment, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Ultrasound Contrast Agents segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$570.7 Million While China is Forecast to Grow at 7.8% CAGR

The Contrast Enhanced Ultrasound market in the U.S. is estimated at US$570.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$552.7 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Contrast-Enhanced Ultrasound Market – Trends, Innovations & Growth Drivers

Why Is Contrast-Enhanced Ultrasound Gaining Importance in Medical Imaging?

Contrast-enhanced ultrasound is rapidly transforming the field of medical imaging, offering a safer, cost-effective, and highly detailed diagnostic alternative to traditional imaging modalities such as CT and MRI. By using microbubble contrast agents, this technology enhances the visualization of blood flow, vascular structures, and tissue perfusion, significantly improving diagnostic accuracy in various clinical applications. Unlike conventional ultrasound, which often struggles to differentiate between similar tissue densities, contrast-enhanced ultrasound provides real-time imaging with higher sensitivity, allowing for better detection of abnormalities such as tumors, inflammation, and ischemic regions.

One of the major factors driving the adoption of contrast-enhanced ultrasound is its safety profile. Traditional contrast agents used in CT and MRI scans contain iodine and gadolinium, which pose risks of allergic reactions and nephrotoxicity, especially in patients with kidney dysfunction. In contrast, microbubble-based ultrasound contrast agents have an excellent safety record, as they are biologically inert and quickly eliminated from the body. Additionally, contrast-enhanced ultrasound does not involve ionizing radiation, making it a preferred choice for pediatric and pregnant patients. The demand for non-invasive, radiation-free imaging solutions is increasing, making contrast-enhanced ultrasound a valuable tool in modern diagnostic workflows.

How Are Technological Advancements Enhancing Contrast-Enhanced Ultrasound?

Advancements in ultrasound imaging technology have significantly improved the capabilities and accuracy of contrast-enhanced ultrasound, making it more effective in detecting and characterizing various pathologies. One of the most notable innovations is the development of real-time perfusion imaging, which allows clinicians to assess microvascular blood flow dynamics and identify abnormalities in tissues and organs with greater precision. This is particularly useful in oncology, where enhanced visualization of tumor vascularity can help differentiate between benign and malignant lesions, aiding in early cancer detection and treatment planning.

Another key advancement is the integration of artificial intelligence and machine learning in contrast-enhanced ultrasound analysis. AI-driven image interpretation algorithms can automatically detect and quantify changes in perfusion patterns, reducing operator dependency and improving diagnostic consistency. Additionally, new-generation ultrasound machines feature higher spatial resolution, improved harmonic imaging, and enhanced Doppler capabilities, further refining contrast-enhanced ultrasound’s ability to visualize blood flow and tissue perfusion. With these technological improvements, contrast-enhanced ultrasound is becoming an essential tool in precision medicine, offering tailored imaging solutions for various medical conditions.

What Are the Key Industry Applications of Contrast-Enhanced Ultrasound?

Contrast-enhanced ultrasound is being increasingly utilized across multiple medical specialties, revolutionizing the way clinicians diagnose and monitor diseases. One of the primary applications is in hepatology, where it is used to assess liver lesions, cirrhosis, and hepatic perfusion abnormalities. The ability of contrast-enhanced ultrasound to differentiate between benign and malignant liver tumors has made it a preferred imaging method in liver cancer screening, particularly for patients with chronic liver disease. Additionally, it plays a critical role in guiding liver biopsies and monitoring treatment response in hepatocellular carcinoma patients.

In cardiology, contrast-enhanced ultrasound is widely used for evaluating myocardial perfusion, detecting ischemic heart disease, and assessing cardiac function. By enhancing the visualization of microvascular blood flow, it helps cardiologists detect subtle perfusion defects that may not be visible on standard echocardiography. Contrast-enhanced ultrasound is also gaining traction in nephrology, where it assists in diagnosing kidney diseases, assessing renal perfusion, and detecting vascular abnormalities. Other emerging applications include oncology, where it aids in the detection of breast, prostate, and pancreatic cancers, as well as musculoskeletal imaging for evaluating inflammatory conditions and soft tissue vascularization. As the medical community continues to recognize the advantages of contrast-enhanced ultrasound, its use is expanding across various diagnostic and interventional procedures.

What Factors Are Driving Growth in the Contrast-Enhanced Ultrasound Market?

The growth in the contrast-enhanced ultrasound market is driven by several factors, including increasing demand for non-invasive imaging techniques, advancements in ultrasound technology, and the growing prevalence of chronic diseases requiring detailed vascular assessment. As healthcare providers seek safer and more cost-effective alternatives to CT and MRI, contrast-enhanced ultrasound is emerging as a preferred imaging modality due to its radiation-free nature and high diagnostic accuracy. The rising incidence of liver disease, cardiovascular disorders, and cancer has further accelerated the need for advanced imaging solutions, positioning contrast-enhanced ultrasound as a critical tool in disease detection and management.

Another key driver is the integration of artificial intelligence and real-time image analysis, which is enhancing the accuracy and efficiency of contrast-enhanced ultrasound interpretation. The increasing adoption of portable and point-of-care ultrasound systems is also fueling market growth, allowing for broader accessibility in emergency medicine, critical care, and outpatient settings. Additionally, regulatory approvals and expanded reimbursement policies for contrast-enhanced ultrasound procedures are encouraging greater adoption among healthcare providers. As the demand for real-time, high-resolution imaging continues to grow, contrast-enhanced ultrasound is set to become an indispensable part of modern medical diagnostics, providing faster, safer, and more precise imaging solutions across a wide range of clinical applications.

SCOPE OF STUDY:

The report analyzes the Contrast Enhanced Ultrasound market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Ultrasound Equipment, Ultrasound Contrast Agents); CEUS Type (Non-Targeted CEUS, Targeted CEUS); End-Use (Hospitals End-Use, Clinics End-Use, Ambulatory Diagnostic Centers End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Acusphere Inc.
• Alpinion Medical Systems
• BK Medical Holding Company Inc.
• Bracco Diagnostic Inc.
• Canon Medical Systems Corporation
• Chison Medical Technology Co., Ltd.
• ContextVision AB
• Esaote S.p.A.
• FUJIFILM VisualSonics Inc.
• GE Healthcare
• Hitachi Healthcare
• Koninklijke Philips N.V.
• Lantheus Medical Imaging, Inc.
• Leriva Pharma S.A.
• nanoPET Pharma GmbH
• Samsung Healthcare
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Siemens Healthineers
• Trivitron Healthcare Pvt. Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.